A Rakuten Company

More titles to consider

Shopping Cart

itemsitem

Synopsis

“Desperate patients, international geopolitics, pharmaceutical competition, governmental secrecy, a race against time-sounds like the stuff of a best-selling novel. But, no. It is “The Remarkable Story of Copaxone®,” In this book, Dr. Kenneth P. Johnson, a highly respected scientist and world-renowned expert on multiple sclerosis, recounts the fascinating tale of the development and rise to prominence of the drug Copaxone®, one of the first agents to significantly impact the course of multiple sclerosis, an often devastating disease of the brain, spinal cord, and optic nerves.” From the Foreword by Aaron Miller, MD

Multiple sclerosis (MS) is the most common crippling neurologic disease of young adults. Its course is unpredictable; people with the disease never know when new symptoms may appear or if improvement will follow. Virtually every therapy for any human disease had been considered and tried, without finding a useful treatment. This understandably led to despair for people with MS and to frustration and disappointment for clinicians.

The development of Copaxone® is among the most unique of modern drug discoveries. Not only is it the enduring legacy of brilliant and determined scientists working over decades; it is also the story of The Weizmann Institute of Science and Teva Pharmaceutical Industries Ltd., two organizations that grew and prospered in spite of a most chaotic and dangerous environment during the early years of the State of Israel. Courage, focus, and dedication to high ideals, as well as excellent science, are the essence of this story.

People who read this also enjoyed

Get a 1 year subscription
for / issue

You can read this item using any of the following Kobo apps and devices:

  • DESKTOP
  • eREADERS
  • TABLETS
  • IOS
  • ANDROID
  • BLACKBERRY
  • WINDOWS